Repligen Shares Sold by Blue Whale Capital

Biotechnology company sees institutional investor reduce stake

Mar. 11, 2026 at 8:52am

Got story updates? Submit your updates here. ›

Blue Whale Capital LLP, an institutional investor, reduced its position in Repligen Corporation (NASDAQ:RGEN) by 15.5% during the 3rd quarter, according to a recent SEC filing. The firm now owns 243,101 shares of the biotechnology company's stock, making it approximately 1.8% of Blue Whale Capital's holdings.

Why it matters

Repligen is a prominent biotechnology company that develops and manufactures high-value consumable products for bioprocessing applications. Changes in institutional ownership can signal shifts in investor sentiment and potentially impact the stock price.

The details

According to the SEC filing, Blue Whale Capital sold 44,585 shares of Repligen stock during the 3rd quarter. The firm now owns approximately 0.43% of Repligen's outstanding shares, valued at $32,495,000 at the end of the quarter.

  • Blue Whale Capital reduced its Repligen stake during the 3rd quarter of 2026.

The players

Blue Whale Capital LLP

An institutional investor that previously owned a 1.8% stake in Repligen Corporation.

Repligen Corporation

A biotechnology company that develops and manufactures high-value consumable products for bioprocessing applications.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Blue Whale Capital's Repligen holdings suggests a potential shift in investor sentiment around the biotechnology company, though the overall impact remains to be seen. Repligen's performance and strategic direction will continue to be closely watched by the investment community.